Gary K. Lee - 20 Aug 2025 Form 4 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Role
Chief Scientific Officer
Signature
/s/ Charles W. Newton, Attorney-in-Fact
Issuer symbol
LYEL
Transactions as of
20 Aug 2025
Transactions value $
$-15,320
Form type
4
Filing time
22 Aug 2025, 16:02:06 UTC
Previous filing
13 Aug 2025
Next filing
29 Oct 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Lee Gary K. Chief Scientific Officer C/O LYELL IMMUNOPHARMA, INC., 201 HASKINS WAY, SOUTH SAN FRANCISCO /s/ Charles W. Newton, Attorney-in-Fact 22 Aug 2025 0001907345

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LYEL Common Stock Award $0 +8,000 +89.3% $0.000000 16,957 20 Aug 2025 Direct F1
transaction LYEL Common Stock Sale $-15,320 -1,453 -8.57% $10.54 15,504 21 Aug 2025 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Pursuant to performance-based restricted stock units granted to the reporting person on February 9, 2024, 4,000 shares were issued on the Transaction Date upon the achievement of certain performance criteria certified by the compensation committee of the Issuer's board of directors on the Transaction Date and 4,000 shares will be issued on August 20, 2026, subject to the reporting person providing service through such date.
F2 Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.
F3 The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $10.49 to $10.64 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.